KURA
Next earnings: Aug 6, 2026
Signal
Mixed11
Price
1
Move-5.34%Selling pressure
Volume
1
Volume1.0× avgNormal activity
Technical
1
RSIRSI 61Momentum positive
PRICE
Prev Close
9.74
Open
9.66
Day Range9.18 – 9.79
9.18
9.79
52W Range5.45 – 12.49
5.45
12.49
54% of range
VOLUME & SIZE
Avg Volume
1.4M
FUNDAMENTALS
P/E Ratio
-2.8x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.12
Market-like
Key MetricsTTM
Market Cap$818.50M
Revenue TTM$71.64M
Net Income TTM-$294.57M
Free Cash Flow-$84.46M
Gross Margin94.7%
Net Margin-411.2%
Operating Margin-443.5%
Return on Equity-142.0%
Return on Assets-45.1%
Debt / Equity0.22
Current Ratio6.15
EPS TTM$-3.32
ANALYST COVERAGE15 analysts
BUY
+133.2%upside to target
L $15.00
Med $21.50consensus
H $28.00
Buy
1493%
Hold
17%
14 Buy (93%)1 Hold (7%)0 Sell (0%)
Full report →
Upcoming Events
EEarnings Report
Tomorrow
May 18
DEx-Dividend
In 89 days
Aug 14
PDividend Pay
In 116 days
Sep 10

KURA News

About

at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Troy Wilson
Francis J. BurrowsChief Scientific Officer
Mollie LeoniChief Medical Officer
Roger BakaleSenior Vice President of Manufacturing & Supply Chain
Troy Edward WilsonChairman, Chief Executive Officer & President
Brian T. PowlChief Commercial Officer
Greg MannSenior Vice President of Investor Relations & Corporate Affairs
Samir VattompadamSenior Vice President of Global Program Leadership
Thomas DoyleSenior Vice President of Finance & Accounting
Kathleen FordChief Operating Officer
Teresa Brophy BairChief Legal Officer & Corporate Secretary